Bioventus (BVS) Total Current Liabilities (2020 - 2026)

Bioventus (BVS) has 7 years of Total Current Liabilities data on file, last reported at $148.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 15.25% year-over-year to $148.1 million; the trailing twelve-month figure through Mar 2026 stood at $148.1 million (down 15.25% YoY), and the FY2025 full-year result was $160.4 million, down 23.77% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $148.1 million, down from $160.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $304.0 million in Q4 2022 and bottomed at $148.1 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $179.1 million (2023), against an average of $196.0 million.
• The widest annual swing landed in 2022, when Total Current Liabilities jumped 79.44%; it then sank 44.22% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $304.0 million in 2022, then tumbled by 42.27% to $175.5 million in 2023, then grew by 19.89% to $210.4 million in 2024, then fell by 23.77% to $160.4 million in 2025, then slipped by 7.66% to $148.1 million in 2026.
• The last three Total Current Liabilities figures came in at $148.1 million (Q1 2026), $160.4 million (Q4 2025), and $161.8 million (Q3 2025), per Business Quant data.

Peer Comparison